🐾 Vasotop R tablets 2.5 mg 28 pcs fl, 3 pcs

Vasotop P is a hypotensive drug. The constituent of the drug, ramipril, is an angiotensin-converting enzyme (ACE) inhibitor which, by inhibiting angiotensin II synthesis, reduces its vasoconstrictor effect and stimulating effect on aldosterone secretion, and also inhibits bradykinin breakdown. Ramipril has no significant effect on renal blood flow (in some cases, it increases it) and on glomerular filtration rate. The drug does not cause development of compensatory tachycardia. The maximum hypotensive effect occurs 1 to 3 hours after taking the drug and lasts for 24 hours. At daily use of Vasotop R decrease in arterial pressure occurs gradually during 3 – 4 weeks and remains within physiological norm during the whole period of treatment. Abrupt withdrawal of the drug does not lead to a rapid increase in blood pressure. Vasotop P has cardioprotective effect due to ACE inhibition in myocardium and bradykinin accumulation, and also promotes the inverse development of myocardial hypertrophy in animals with arterial hypertension. After oral administration, ramipril is rapidly absorbed in an amount equal to at least 50-60% of the administered dose. Primary metabolism of ramipril occurs in liver. Ramipril derivative – ramiprilat – is formed. Ramiprilat is about 6 times more active inhibitor of ACE than ramipril. Binding to plasma proteins is 73% for ramipril and 56% for ramiprilat. After a daily single dose of Vasotop P, the steady-state plasma concentration of ramiprilat is reached by 4 days. About 60% of the drug is excreted in the urine and about 40% in the feces (mainly as metabolites). With impaired renal function, excretion of ramipril and its metabolites slows down in proportion to the decrease in creatinine clearance. According to the degree of effect on the body of warm-blooded animals, Vasotop P belongs to the low-hazardous substances.

Indications

Active ingredient

Composition

How to take, the dosage

Special Instructions

Contraindications

Side effects